Various circulatory agents including vasopressors such as angiotensin II, endothelin-1, and vasopressin and vasodilators such as nitric oxide, endocannabinoid, and substance P are implicated in cirrhosis-induced portal hypertension and splanchnic vasodilation, respectively [77,78]. The gene discussed is TAC1; the disease is liver disorder.